Precautionary Recall of Ramipril 10mg Batch GR174091
Summary
Crescent Pharma Limited is recalling one batch of Ramipril 10mg capsules (batch GR174091) as a precautionary measure due to a potential manufacturing error which may mean some cartons contain blister strips of a lower dose, specifically Ramipril 5mg. Both product batches were manufactured at the same manufacturing site, and the error appears to have occurred during secondary packaging of the cartons. The MHRA has advised pharmacy and healthcare professionals to stop supplying the impacted batch and return all remaining stock to their suppliers.
“Crescent Pharma Limited is recalling one batch of Ramipril 10mg capsules as a precautionary measure due to a potential manufacturing error which may mean some cartons contain blister strips of a lower dose, specifically Ramipril 5mg.”
About this source
The Medicines and Healthcare products Regulatory Agency is the UK's medicines and medical devices regulator. MHRA publications include drug safety alerts, device field safety notices, Class 1-4 defect recalls, guidance updates, and the monthly medicines shortage list. Around 55 publications a month. Device field safety notices in particular are useful because MHRA often publishes them hours before other European regulators (ANSM, BfArM) surface the same recall. Watch this if you manufacture or distribute medicines or medical devices in the UK and EU, run a hospital pharmacy, advise on MHRA licensing, or follow post-market surveillance signals across European markets.
What changed
Crescent Pharma Limited has initiated a precautionary Class 2 recall for one batch of Ramipril 10mg capsules (GR174091) following identification that some sealed cartons may contain Ramipril 5mg blister strips due to a secondary packaging error at the manufacturing site. The MHRA has directed pharmacy and healthcare professionals to immediately cease supplying the affected batch and return all remaining stock to suppliers.
Patients who have received this batch should verify that the medication name on the carton matches the blister strips inside. Those who have taken an incorrect dose should seek medical advice but should be reassured that the risk is very low, as both strengths treat the same conditions and any impact would be gradual rather than immediate or life threatening. Pharmacies and healthcare providers should urgently audit their stock for batch GR174091 and coordinate returns through their suppliers.
What to do next
- Check the packaging for batch number GR174091
- If the 10 mg carton of Ramipril contains blister strips labelled as Ramipril 5mg capsules, contact your dispensing pharmacy
- Seek medical advice if you believe you have taken any Ramipril 5mg capsules in error and are experiencing adverse effects
- Report any suspected adverse reactions via the MHRA Yellow Card scheme
Archived snapshot
Apr 20, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Press release
Precautionary recall of blood pressure medication after manufacturing error
The MHRA has advised pharmacy and healthcare professionals to stop supplying the impacted batch and return all remaining stock to their suppliers.
From: Medicines and Healthcare products Regulatory Agency Published 20 April 2026
Crescent Pharma Limited is recalling one batch of Ramipril 10mg capsules as a precautionary measure due to a potential manufacturing error which may mean some cartons contain blister strips of a lower dose, specifically Ramipril 5mg.
This follows a complaint from a patient where it was identified that, inside a sealed carton of Ramipril 10mg capsules, one blister pack of Ramipril 5mg capsules was found. Both product batches were manufactured at the same manufacturing site, and the error appears to have occurred during secondary packaging of the cartons.
The risk to patients of taking the lower dose of this medicine for a limited time is very low.
Dr Alison Cave, MHRA Chief Safety Officer, said:
“If you take Ramipril 10mg, check the packaging for batch number GR174091. The batch number and expiry date information can be found on the outer carton. If you have received this batch, check that the medication name on the carton matches the blister strips inside.
“If the 10 mg carton of Ramipril contains blister strips that are labelled as Ramipril 5mg capsules, contact your dispensing pharmacy. If the carton contains blister strips that are correctly labelled as Ramipril 10mg capsules, you do not need to take further action.”
If you have an impacted pack or previously received this batch and you believe you have taken any Ramipril 5mg capsules that were included in error and are currently experiencing any adverse effects, please seek medical advice. Please take the leaflet that came with your medicine and any remaining tablets with you to your pharmacy or GP practice. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme.
If you’ve already taken Ramipril 5mg, please be reassured that there is a very low risk to your health. Both strengths of the medication are used to treat high blood pressure, heart failure, and kidney disease. Any possible impact of a lower dose of Ramipril is expected to be gradual rather than immediate or life threatening.
The MHRA has advised pharmacy and healthcare professionals to stop supplying the impacted batch and return all remaining stock to their suppliers.
Notes to editors
- Please see MHRA’s Class 2 recall for further information and images of the affected product.
- The MHRA is responsible for regulating all medicines and medical devices in the UK by ensuring they work and are acceptably safe. All our work is underpinned by robust and fact-based judgements to ensure that the benefits justify any risks.
- The MHRA is an executive agency of the Department of Health and Social Care.
- For media enquiries, please contact the newscentre@mhra.gov.uk, or call on 020 3080 7651.
Share this page
The following links open in a new tab
Updates to this page
Published 20 April 2026
Mentioned entities
Parties
Related changes
Get daily alerts for MHRA Guidance & Safety
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from MHRA.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when MHRA Guidance & Safety publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.